S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
How to make money with penny stocks 
What is the consumer staples sector?
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
6 best online and direct marketing retail stocks to invest in
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
How to make money with penny stocks 
What is the consumer staples sector?
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
6 best online and direct marketing retail stocks to invest in
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
How to make money with penny stocks 
What is the consumer staples sector?
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
6 best online and direct marketing retail stocks to invest in
What does consumer price index measure?
S&P 500   4,549.34
DOW   36,054.43
QQQ   385.05
14 best consumer staples dividend stocks
How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology (Ad)
Ex dividend date vs record date: What’s the difference?
How to find blue-chip dividend stocks
Americans Now Favor Gold Over Stocks as an Investment Vehicle (Ad)
How to make money with penny stocks 
What is the consumer staples sector?
Lithium Discovery So BIG You Can't Miss it, Even From Space (Ad)
6 best online and direct marketing retail stocks to invest in
What does consumer price index measure?

Cellectar Biosciences Stock Price, News & Analysis (NASDAQ:CLRB)

$2.55
0.00 (0.00%)
(As of 12/6/2023 ET)
Compare
Today's Range
$2.45
$2.62
50-Day Range
$1.94
$2.91
52-Week Range
$1.25
$3.15
Volume
110,925 shs
Average Volume
232,270 shs
Market Capitalization
$31.34 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.00

Cellectar Biosciences MarketRank™ Stock Analysis

Analyst Rating
0.00 Rating Score
Upside/​Downside
292.2% Upside
$10.00 Price Target
Short Interest
Healthy
6.87% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.85) to ($2.30) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.32 out of 5 stars

Medical Sector

888th out of 957 stocks

Pharmaceutical Preparations Industry

378th out of 399 stocks


CLRB stock logo

About Cellectar Biosciences Stock (NASDAQ:CLRB)

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Stock Price History

CLRB Stock News Headlines

Lithium Discovery So BIG You Can't Miss it, Even From Space
With the green energy transition well underway, lithium demand is rapidly outpacing projected supply. While companies frantically search for new sources of this critical metal, one small company is sitting on a massive claim in North America - So big in fact that it can clearly be seen from space!
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
CLRB - Cellectar Biosciences, Inc.
Cellectar Biosciences GAAP EPS of -$0.76
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/07/2021
Today
12/06/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
3/14/2024

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLRB
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$10.00
High Stock Price Target
$10.00
Low Stock Price Target
$10.00
Potential Upside/Downside
+292.2%
Consensus Rating
Rating Score (0-4)
0.00
Research Coverage
0 Analysts

Profitability

Net Income
$-28,600,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.51 per share

Miscellaneous

Free Float
11,723,000
Market Cap
$31.34 million
Optionable
Not Optionable
Beta
1.10
Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Mr. James V. Caruso (Age 64)
    President, CEO & Director
    Comp: $846.48k
  • Mr. Chad J. Kolean CPA (Age 59)
    VP, CFO & Secretary
    Comp: $453.22k
  • Mr. Jarrod Longcor (Age 50)
    Chief Operating Officer
    Comp: $625.32k
  • Mr. Darrell Shane Lea (Age 50)
    Chief Commercial Officer
  • Dr. Andrei Shustov M.D. (Age 52)
    Senior Vice President of Medical














CLRB Stock Analysis - Frequently Asked Questions

What is Cellectar Biosciences' stock price target for 2024?

0 Wall Street research analysts have issued 12-month price targets for Cellectar Biosciences' shares. Their CLRB share price targets range from $10.00 to $10.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 292.2% from the stock's current price.
View analysts price targets for CLRB
or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2023?

Cellectar Biosciences' stock was trading at $1.71 at the start of the year. Since then, CLRB shares have increased by 49.1% and is now trading at $2.55.
View the best growth stocks for 2023 here
.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a decline in short interest in the month of November. As of November 15th, there was short interest totaling 800,100 shares, a decline of 7.2% from the October 31st total of 861,800 shares. Based on an average trading volume of 708,100 shares, the short-interest ratio is currently 1.1 days. Currently, 6.9% of the company's shares are sold short.
View Cellectar Biosciences' Short Interest
.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our CLRB earnings forecast
.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) released its quarterly earnings data on Sunday, November, 7th. The biopharmaceutical company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.10) by $0.10.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

Who are Cellectar Biosciences' major shareholders?

Cellectar Biosciences' stock is owned by many different retail and institutional investors. Top institutional shareholders include AIGH Capital Management LLC (6.82%), Worth Venture Partners LLC (2.81%) and Acuta Capital Partners LLC (1.22%). Insiders that own company stock include Dov Elefant, James V Caruso and Jarrod Longcor.
View institutional ownership trends
.

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CLRB) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -